Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HENGRUI PHARMA) filed its Monthly Return for June 2026, highlighting stable Hong Kong–listed H-share capital alongside increased A-share treasury holdings driven by on-market repurchases.
Authorised and Issued Share Capital • Authorised/registered share capital remained unchanged at 6.64 billion shares (RMB 1 par value). • H-shares: Issued volume stayed at 258.20 million; no treasury H-shares are held. • A-shares: Issued shares decreased by 1.41 million to 6.37 billion after transferring the same amount into treasury. Treasury A-shares rose to 8.31 million.
June Share Repurchases Between 4–17 June 2026, the company repurchased 1.41 million A-shares on the Shanghai Stock Exchange at prices ranging from RMB 45.62 to RMB 47.27, spending approximately RMB 66.10 million. The repurchased stock is earmarked for existing Employee Stock Ownership Schemes (ESOPs) covering 2022–2025.
Public Float Compliance HENGRUI PHARMA confirmed compliance with Hong Kong’s Main Board Rule 13.32D, maintaining a 3.9% public float for its H-shares, equivalent to a market value of HK$16.65 billion—well above the HK$1 billion threshold.
Capital Structure Snapshot (30 June 2026) • Total issued shares: 6.63 billion (A-shares 6.37 billion; H-shares 0.26 billion) • Treasury shares: 8.31 million A-shares; zero H-shares
No movements were recorded under share option schemes, warrants, or convertible securities during the month.
